President Trump’s plan would send a huge number of refugees to Jordan, adding new frictions to the kingdom’s often tense, sometimes violent history with displaced Palestinians. By Ephrat Livni ...
King Abdullah II of Jordan said Tuesday that Arab nations are unified in their opposition to displacing Palestinians from Gaza, following a meeting with President Trump in which the president ...
President Trump met with the king of Jordan at the White House on Tuesday and insisted he would move forward with his vision for the United States to "take" the Gaza Strip, send its residents to ...
President Trump met with King Abdullah II of Jordan on Tuesday, where he doubled down on a controversial proposal for the U.S. to take over the Gaza Strip amid pressure he’s putting on ...
Jordan Binnington will start Canada's opening game at the 4 Nations Face-Off against Sweden in Montreal on Wednesday, head coach Jon Cooper confirmed. Cooper, who added Hill will be the team's ...
Most Air Jordan 4s are made of leather or suede or even nubuck. But sometimes (just sometimes), they're crafted from canvas like Affleck's Air Jordan 4 SE ‘Black Canvas.’ First released two ...
National Bank raised the firm’s price target on EMX Royalty (EMX) to C$4.25 from C$4 and keeps an Outperform rating on the shares. Published first on TheFly – the ultimate source for real-time ...
Portfolio Receipts: $2.8 billion for 2024, representing 13% growth in Royalty Receipts ... 9.8% of Portfolio Receipts in Q4 and 8.4% for the year. Net Interest Paid: $113 million for the full ...
Christopher Hite; Vice Chairman, Executive Vice President; Royalty Pharma PLC Marshall Urist ... And with that, please advance to slide 4. Our speakers on the call today are Pablo Legorreta ...
Cash and equivalents: $929 million, with a pro forma of $1.4 billion after the MorphoSys sale. Royalty Pharma's actual EPS of $0.3531 fell short of the forecasted $0.9849, marking a significant miss.
NEW YORK (AP) — NEW YORK (AP) — Royalty Pharma (RPRX) on Tuesday reported fourth-quarter net income of $208 million. The New York-based company said it had net income of 35 cents per share.
Refer to Table 4 for Royalty Pharma’s reconciliation of each non-GAAP measure to the most directly comparable GAAP financial measure, net cash provided by operating activities. Capital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results